Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation  by Bräutigam, Karen et al.
Combination of Enzastaurin
and Pemetrexed Inhibits Cell
Growth and Induces Apoptosis
of Chemoresistant Ovarian
Cancer Cells Regulating
Extracellular Signal–Regulated
Kinase 1/2 Phosphorylation1,2
Karen Bräutigam*,†, Dirk Olaf Bauerschlag*,‡,
Marion Tina Weigel*, Julia Biernath-Wüpping*,
Thomas Bauknecht§, Norbert Arnold*,
Nicolai Maass*,‡ and Ivo Meinhold-Heerlein*,‡
*Department of Gynecology and Obstetrics, University
Hospital Schleswig-Holstein, Kiel, Germany; †Burnham
Institute for Medical Research, La Jolla, CA, USA;
‡Department of Gynecology and Obstetrics, University
Hospital Aachen, Aachen, Germany; §Medical-Oncology,
Lilly Deutschland GmbH, Bad Homburg, Germany
Abstract
New strategies in the therapy for malignant diseases depend on a targeted influence on signal transduction path-
ways that regulate proliferation, cell growth, differentiation, and apoptosis by the activation of serine/threonine
kinases. Enzastaurin (LY317615.HCl), a selective inhibitor of protein kinase Cβ (PKCβ), is one of these new drugs
and causes inhibition of proliferation and induction of apoptosis. Pemetrexed, a multitarget inhibitor of folate path-
ways, is broadly active in a wide variety of solid tumors. Therefore, the effect of enzastaurin and the combination
treatment with pemetrexed was analyzed when applied to the drug-sensitive ovarian cancer cell line HEY and
various subclones with drug resistance against cisplatin, etoposide, docetaxel, and paclitaxel, as well as peme-
trexed, and gemcitabine. In these novel chemoresistant subclones, the expression of the enzastaurin targets
PKCβII and glycogen synthase kinase 3β (GSK3β) was analyzed. Exposition to enzastaurin showed various inhibitory
effects on phosphorylated forms of GSK3β and the mitogen-activated protein kinase extracellular signal–regulated
kinase 1/2. Cell proliferation experiments identified the cell line–specific half-maximal inhibitory concentration values
of enzastaurin and a synergistic inhibitory effect by cotreatment with the antifolate pemetrexed. Induction of apop-
tosis by enzastaurin treatment was investigated by Cell Death Detection ELISA and immunoblot analyses. Simul-
taneous treatment with pemetrexed resulted in an enhanced inhibition of proliferation and induction of apoptosis
even in partial enzastaurin-resistant cells. Therefore, the combinational effect of enzastaurin and pemetrexed can
have promise in clinical application to overcome the fast-growing development of resistance to chemotherapy in
ovarian cancer.
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Introduction
Ovarian cancer accounts for the highest tumor-related mortality among
women whose conditions were diagnosed with gynecologic malignancy.
Although the incidence of 21,650 new cases accounts for only 3% of all
female cancers, 15,520 patients in the United States are predicted to die
of ovarian cancer in 2008, as estimated by the American Cancer Society
[1]. This high ratio of death to incidence is mostly due to late-stage
diagnosis caused byminimal and rather unspecific symptoms. The poor
prognosis of advanced stage ovarian cancer is reflected in a 5-year sur-
vival rate of less than 30% for patients diagnosed with FIGO stage III
or IV disease [2]. Cytoreductive surgery is one of the most important
prognostic factors in ovarian cancer [3], and adjuvant chemotherapy
with a combination of carboplatin and paclitaxel is considered the
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criterion standard [4]. Although this is a potent combination, many
patients experience a recurrence within 6 months of the last cycle of
chemotherapy. These prognostically unfavorable early relapses are pre-
sumed to be platinum- and taxane-resistant and associated with only
short-term survival. Thus, overcoming chemotherapy resistance remains
a key problem in the treatment of advanced ovarian cancer, and con-
sequently, new drugs targeting cancer-specific molecules are needed.
In cancer cells, the balance between apoptosis and cell proliferation is
adjusted in favor of cell growth. Protein kinases C (PKCs) are a family
of serine/threonine kinases comprising at least 12 isoforms that are in-
volved in tumor formation and progression [5,6]. Several reports have
shown that activation of PKC is required for tumor-induced angiogene-
sis [7,8]. In addition, PKC activation triggers signaling through the ras/
extracellular signal–regulated kinase 1/2 (ERK1/2) pathway, which
may be involved in the controlling of cellular proliferation and apopto-
sis [9–11] as well as the induction of intestinal cell invasiveness [12].
Protein kinase C activation requires the activity of phosphatidylinositol-
dependent kinase 1, a key effector kinase, activated immediately down-
stream of the phosphatidylinositol 3-kinase (PI3K), which gives rise to
a link between the activities of PKC and PI3K/AKT pathway, a promi-
nent regulatory pathway governing the apoptotic response [13]. Further
evidence for overlapping signaling pathways is the direct phosphory-
lation of AKT at Ser473 by PKCα, PKCβ, and PKCη [14–16]. More-
over, both PKC and AKT can phosphorylate glycogen synthase kinase
3β at Ser9 (GSK3β) [17–19]. Cross talk between PKC and the PI3K/
AKT pathway may be an attractive mechanism by which PKCs influ-
ence the apoptotic response. Furthermore, the resistance of cancer cells
to treatment can be attributed in many instances to activation of intra-
cellular signaling pathways involved in survival, such as the Ras-Raf-
MEK-ERK1/2 or the PI3K/AKT pathway [20].
The contribution of PKCs in tumor progression initiates the devel-
opment of novel anticancer therapeutics targeting PKC. Enzastaurin
(LY317615.HCl; Eli Lilly and Company, Indianapolis, IN), an acyclic
bisindolymaleimide, was developed as a potent and selective ATP
competitive inhibitor of PKCβ [21]. Enzastaurin has shown to be anti-
apoptotic and antiproliferative in tumor cells in vitro and demonstrated
in vivo efficacy in small cell lung, colon, renal, glioma, and multiple
myeloma tumor animal models [22–24]. The mechanisms of action
leading to tumor suppression in vivo seem to be complex. In addition
to PKC inhibition, enzastaurin impedes the PI3K/AKT pathway, as
evaluated by the inhibition of GSK3β and AKT phosphorylation in
tumor cells and tumor tissue [23,25].
The aim of our investigation was to evaluate whether enzastaurin
can cause apoptosis and growth inhibition of chemotherapy-resistant
ovarian cancer cell lines. Using the parental HEY cell line, subclones
were developed with selective resistance against cisplatin, etoposide,
docetaxel, paclitaxel, pemetrexed, gemcitabine, and enzastaurin as con-
trol cell line, respectively. Inhibition of proliferation and induction of
apoptosis were examined in all analyzed cell lines. Because we observed
only partial inhibition of proliferation at clinically achievable concen-
trations [26], we also questioned whether therapeutic efficacy could be
enhanced by a combination treatment with pemetrexed. Pemetrexed
(Alimta; Eli Lilly and Company) is a novel multitargeted antifolate
that potently inhibits thymidylate synthase and, to a much lesser extent,
glycinamide ribonucleotide formyltransferase and dihydrofolate reduc-
tase, thus directly decreasing the growth rate of tumor cells by limiting
the available pools of thymidine required for DNA synthesis [27].
Pemetrexed induces apoptosis in a broad spectrum of solid tumors,
including breast, colorectal, gastric, cervical, bladder, and non–small
cell lung cancer (NSCLC) [28]. Furthermore, it has been associated
with a significant reduction of phosphorylated AKT as well as a syn-
ergistic antiproliferative effect in combination treatment with gem-
citabine in human NSCLC cells [29]. Pemetrexed has also shown
clinically relevant activity in combination with other chemotherapeu-
tic agents such as gemcitabine in solid tumors, including ovarian can-
cer [30,31].
Materials and Methods
Drugs and Antibodies
Enzastaurin (10 mM stock aliquots in DMSO at −20°C), peme-
trexed, and gemcitabine (100 mM stock aliquots in PBS at −20°C)
were obtained from Eli Lilly. Cisplatin, etoposide, docetaxel, and pacli-
taxel were purchased from Sigma (Taufkirchen, Germany) and stored as
recommended by the manufacturer. Primary antibodies were obtained
from New England Biolabs [Frankfurt am Main, Germany; phospho-
GSK3β (Ser9), phospho-AKT (Ser473), AKT, phospho-ERK1/2
(Thr202/Tyr204), ERK1/2, caspase 8, caspase 9, poly(ADP-ribose) poly-
merase (PARP)], BD Biosciences (Heidelberg, Germany; GSK3β), and
Sigma (β-actin). Secondary, either antimouse or antirabbit, antibodies
were purchased from GE Healthcare (München, Germany).
Cell Culture and Cytostatic Drug Resistance Cultivation
The parental ovarian cancer cell line HEY emanated from ascites
cells of a moderately differentiated serous papillary ovarian carcinoma
and served as origin for cultivation of the cytostatic drug-resistant
subpopulations. Cells were treated three times a week with increasing
concentrations of the subsequent cytostatic drugs (median duration,
8-10 months) until the cells exhibited significant resistance. Long-
term cultivation was done with growth media RPMI 1640 (Biochrom,
Berlin, Germany) containing 2.0 g/L NaHCO3, stable glutamine, 10%
fetal calf serum (Invitrogen, Karlsruhe, Germany), 50 U/ml penicillin
(Biochrom), and 50 mg/ml streptomycin (Biochrom) at 37°C and
5% CO2. The appropriate cytostatic drug for each of the resistant sub-
clones was additionally supplied (2 μg/ml cisplatin, 5 μg/ml etoposide,
15 ng/ml docetaxel, 40 ng/ml paclitaxel, 3 μM pemetrexed, 5 μM
gemcitabine, and 25 μM enzastaurin). Resistance was proven by MTS
Assay from Promega (Mannheim, Germany; Table W1). Stimulation
experiments for immunoblot analyses were performed under serum-
starved conditions.
Cell Proliferation Assay
Inhibition of proliferation was determined with a colorimetric
MTS (3-[4,5-dimethylthiazol-2yl]-5-[3-carboxymethoxyphenyl]-2-
[4-sulfophenyl]-2H tetrazolium) cell proliferation assay (CellTiter96
Aqueous Non-Radioactive Cell Proliferation Assay; Promega). Five
thousand cells were seeded in 96-well microtiter plates (Sarstedt,
Nümbrecht, Germany) in 200 μl of growth medium. After an over-
night attachment period, cells were exposed for 72 hours at 37°C and
5% CO2 to various concentrations of enzastaurin (0.625-40 μM)
and, in subsequent experiments, to denoted concentrations of enzas-
taurin and pemetrexed (10 and 50 nM), alone and in combina-
tion. Control cells received vehicle alone (0.4% DMSO). After the
72 hours of treatment, media were exchanged and 20 μl of Assay
reagent was added to each well. After incubation for an additional
2 hours, the number of viable cells was determined by measuring
the absorption of the generated formazan spectrophotometrically at
490 nm. The proliferation inhibition was indicated by the percentage
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of absorption of sample and control wells. All studies were performed
in triplicate and repeated at least three times independently. To cal-
culate half-maximal inhibitory concentration (IC50) values, the drug
concentration data, x1, x2, …, xn, were logarithm-transformed and
the growth inhibition data, y1, y2,…, yn, were in the range of 0 to 1.
The IC50 values were estimated by plotting x-y and then fit the data
with a straight line after the x-axis is logarithm-transformed [Y = aX +
b; IC50 = (0.5 − b) / a].
Cell Death Detection ELISA
To investigate apoptosis induced by enzastaurin treatment, the Cell
Death Detection ELISA (CDDE) plus (Roche, Mannheim, Germany),
a sandwich enzyme immunoassay for detection of nucleosomes released
during apoptotic process, was performed. Cells (5 × 103 per well) were
disseminated in 96-well microtiter plates (Sarstedt) in 200 μl of growth
medium. After an overnight attachment period, cells were treated with
1, 2, and 10 μMof enzastaurin for 24 hours at 37°C. After accomplish-
ing the ELISA procedure, as recommended by manufacturer, release of
nucleosomes was determined by measuring the absorption spectro-
photometrically at 405 nm. Accumulation of the detached mono-
nucleosomes and oligonucleosomes into the cytoplasm was calculated
as enrichment factor (absorbance of sample/absorbance of corre-
sponding negative control). Assay was performed in duplicate and re-
peated twice.
GSK3β ELISA
The decrease of activated GSK3β by enzastaurin treatment in cell
lysates was determined with the DuoSet IC ELISA from R&D
Systems (Wiesbaden, Germany), containing the basic components
required for the development of sandwich ELISA to measure phos-
phorylated GSK3β. Both untreated cells and cells exposed to 5 μM
enzastaurin were solubilized for different times (0.5-3 hours) in lysis
buffer, 1 mM EDTA, 0.5% Triton X-100, 5 mM NaF, 1 M urea, 1%
Protease Inhibitor Cocktail II (Sigma), and 1% phosphatase inhibitor.
One microgram of total protein was used for the ELISA, which was
performed as recommended by the manufacturer. Results were calcu-
lated by the mean of duplicates of samples and standards subtracted by
the average zero standard.
Immunoblot Analysis
Total cell lysates were prepared and analyzed by immunoblot analy-
sis. Cells, 1 to 5 × 106, were seeded in 10-ml culture dishes and incu-
bated overnight at 37°C and 5% CO2. Both untreated cells and cells
treated with 5 and 10 μM enzastaurin, respectively, were solubilized
for indicated times (0.5-48 hours) in lysis buffer containing 1 mM
EDTA, 0.5% Triton X-100, 5 mM NaF, 1 M urea, 1% Protease In-
hibitor Cocktail II, and 1% phosphatase inhibitor (Sigma). Vortexed
samples were allowed to sit on ice for 1 hour, and sample protein con-
centrations were then quantified using a total protein assay (Bio-Rad,
München, Germany). Equal amounts of protein were separated by
SDS-PAGE and electrotransferred onto a polyvinylidene fluoride
membrane (GE Healthcare). Membranes were blocked and incubated
overnight with antibodies according to the manufacturer’s recommen-
dations. The proteins were visualized by enhanced chemiluminescence
(ECL Plus Reagent; GE Healthcare). In addition, membranes were re-
probed with antibodies against β-actin to ensure equal loading and
transfer of proteins.
Results
Enzastaurin Treatment Suppresses Proliferation and Induces
Apoptosis in the Parental and Cytostatic-Resistant Ovarian
Cancer Cell Lines
To determine the effect of enzastaurin on the parental ovarian can-
cer cell line HEY and its drug-resistant counterparts, cells were cul-
tured with increasing concentrations of enzastaurin (0.63-40 μM) for
72 hours, which resulted in a dose-dependent inhibition of prolifer-
ation in all examined cell lines. The cisplatin-resistant cell line was
the only cytostatic-resistant cell line that exhibited stronger sensitivity
to enzastaurin treatment than the parental HEY cells. Among the re-
maining cytostatic-resistant HEYs, the docetaxel-resistant cell line
displayed the highest resistance to enzastaurin stimulation except
for the enzastaurin-resistant control cell line, as also indicated in the
table (Figure 1A).
To determine whether enzastaurin might induce apoptosis in our
ovarian cancer cell lines, we performed the CDDE. As measured by
oligonucleosomal fragmentation, a concentration of 10 μMenzastaurin
significantly induced apoptosis mainly in cisplatin-resistant and paren-
tal HEYs and also, to a lesser extent, in the etoposide- and paclitaxel-
resistant cell lines. Docetaxel-, pemetrexed-, and gemcitabine-resistant
cells showed only a slight increase of enrichment factor indicating that
enzastaurin stimulation caused nearly no apoptosis after 24 hours in
these cells (Figure 1B).
Decreased Phosphorylation of GSK3β Correlates with
Responsiveness to Enzastaurin
In the following investigation, we sought to examine an effect of
enzastaurin on GSK3β phosphorylation in the cytostatic-resistant
HEYs compared with the parental ones. Already after 30 minutes
of treatment with 5 μM enzastaurin, a broad decrease of phosphor-
ylated GSK3β in all examined HEY cells was observed which arose
again after 3 hours of treatment (Figure 2). The expression pattern of
phosphorylated GSK3β was very different within the untreated cells.
The strongest expression of activated GSK3β was displayed by the
cisplatin- and paclitaxel-resistant cell lines, whereas the parental
HEYs showed a low protein level of phosphorylated GSK3β. There-
fore, a correlation between the sensitivity for enzastaurin and the ex-
pression level of activated GSK3β failed (Figure 2A). In contrast, the
enzastaurin-dependent dephosphorylation seems to correspond to
the response to enzastaurin treatment as demonstrated by the per-
centages of enzastaurin-dependent decrease of phosphorylated GSK3β
(Figure 2C ). Here, the strongest dephosphorylation occurred in
the parental and cisplatin-resistant HEYs, which are known to be
more responsive to enzastaurin than the others. To confirm these
ELISA-based results and validate a real dephosphorylation, immuno-
blot analyses were performed, which reflected the results very well
(Figure 2B). The detection of total GSK3β with nearly identical band
intensity within each cell line indicated that a real dephosphorylation
occurred dependent on enzastaurin treatment. This was additionally
validated by the expression analyses of β-actin.
Enzastaurin Shows a Slight Effect on AKT Phosphorylation
in the Parental HEY Cell Line, and Causes Strong Variations
in Phosphorylation of the Mitogen-Activated Protein
Kinase ERK1/2
Treatment of the various HEY cell lines under identical conditions
as for GSK3β expression—stimulation with 5 μM enzastaurin up to
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3 hours—failed to inhibit AKT activity as detected by immunoblot
experiment with phospho-AKTantibody (data not shown). Therefore,
we checked the inhibition of phosphorylated AKTexpression in paren-
tal HEY cells treated with 10 μM enzastaurin for 3, 6, 12, 24, and
48 hours and could observe a distinct decrease of phosphorylated
AKT after 48 hours of enzastaurin exposition (Figure 3).
The adjacent analysis dealt with enzastaurin affecting the ERK1/2
pathway after treatment with 10 μM enzastaurin for analogous times
in the parental HEY cell line. We could prove an alternating phosphor-
ylation pattern as already demonstrated for GSK3β. A decline of phos-
phorylated ERK occurred after 3 hours with enzastaurin treatment,
which rose again after 6 hours. A strong decrease was displayed after
12 hours of exposition, which increased again after an additional
12 hours, but declined nearly completely after 48 hours (Figure 3).
Combined Exposure of Ovarian Cancer Cell Lines to
Enzastaurin and Pemetrexed Enhances Antiproliferative Effects
Because enzastaurin only partially inhibited the proliferation of
parental and cytostatic-resistant HEY cell lines at clinically achievable
concentrations, we questioned whether antiproliferative effects could
be potentiated by the administration of an additional cytostatic drug
that affects targets involved in PKC-mediated signaling. Cells were
treated with various concentrations of enzastaurin with or without both
10 and 50 nM pemetrexed for 72 hours, and cell proliferation was mea-
sured with an MTS assay. The most promising result was achieved by
the combination treatment of 5 μM enzastaurin plus 50 nM peme-
trexed. Compared with the single treatment with either enzastaurin
or pemetrexed, we could prove a synergistic proliferation inhibition ef-
fect by combined treatment in all examined cell lines, with the expected
exception of the pemetrexed-resistant cells (Figure 4). The docetaxel-
resistant HEYs, which were affected by neither 5 μM enzastaurin nor
50 nM pemetrexed, showed 50% less proliferating cells after the com-
bination treatment. More than 30% of the etoposide-resistant cells,
which did not respond to the single agents, were inhibited by enzastaurin
in combination with pemetrexed. Although both inhibitors were ef-
fective with cisplatin-resistant cells on their own, combined exposition
increased inhibition by another 30%. In the parental, the paclitaxel-
resistant, and gemcitabine-resistant HEYs, not only that 50 nM peme-
trexed caused proliferation inhibition as a single agent but also that a
slight synergistic effect could be observed by the combination treatment.
The enzastaurin-resistant cells responded strongly to pemetrexed alone,
and surprisingly, both drugs caused a slight but even stronger prolifera-
tion inhibition. These results indicate that cotreatment with pemetrexed
exhibits synergistic inhibitory effects on proliferation in ovarian cancer
cell lines resistant against clinically established chemotherapeutics with
the most promising effect in the docetaxel-resistant HEYs.
Figure 1. (A) Dose-dependent inhibition of proliferation due to enzastaurin treatment. Five thousand cells were seeded in 96-well plates
and incubated for 72 hours with rising concentrations of enzastaurin, as indicated. MTS assay was performed as described in the
Materials and Methods section. The parental and various drug-resistant HEYs showed enzastaurin-caused growth inhibition to a certain
extent as indicated by the IC50 values in the table. (B) CDDE validates enzastaurin-induced apoptosis in parental and chemoresistant
HEYs. Cells were treated with indicated enzastaurin concentrations for 24 hours, and CDDE was performed, as described in the Materials
and Methods section.
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Pemetrexed Increases Enzastaurin-Induced Induction of
Apoptosis and Inhibition of Proproliferative Kinases
We could also show that costimulation of pemetrexed increases
apoptosis induced by enzastaurin. HEY cells were treated either with
10 μM enzastaurin or concomitantly with 10 μM enzastaurin plus
50 nM pemetrexed for 3, 6, 12, 24, and 48 hours. General apoptosis
induction was proven by PARP cleavage, induction of the extrinsic
apoptotic pathway by caspase 8 and induction of the intrinsic mito-
chondrial pathway by caspase 9 cleavage using immunoblot analyses.
Partial PARP cleavage occurred after 48 hours of enzastaurin treatment.
Combined treatment with pemetrexed resulted in nearly completely
cleaved PARP, demonstrating increased induction of apoptosis. Investi-
gation of the initiator caspases 8 and 9 also displayed a slight cleavage
into the proapoptotic active proteins by enzastaurin stimulation, which
was additionally enforced by concomitant administration of peme-
trexed (Figure 5).
Subsequent immunoblot experiments were performed to determine
an influence on the enzastaurin-caused dephosphorylation of GSK3β,
AKT, and ERK. Treatment of the HEY cells was done with 10 μM
enzastaurin alone and in combination with 50 nM pemetrexed for 3, 6,
12, 24, and 48 hours. Dephosphorylation of GSK3β was existent in all
enzastaurin-treated samples compared with the untreated cells. Further-
more, we could demonstrate very strong dephosphorylation of GSK3β
after 12 hours of enzastaurin exposition, which is consistent with the
observation identified for the phosphorylation pattern of the mitogen-
activated protein (MAP) kinase ERK. Cotreatment of pemetrexed re-
sulted in a slightly stronger dephosphorylation of GSK3β after 6 hours
but did not affect enzastaurin-caused dephosphorylation at other time
points. Whereas cotreatment up to 12 hours demonstrated no addi-
tional effect on the phosphorylation of AKT, the combined treatment
for 24 and 48 hours caused a stronger dephosphorylation of AKT com-
pared with enzastaurin treatment alone. The enzastaurin-dependent
Figure 2. Effect of enzastaurin treatment on expression pattern of phosphorylated GSK3β in parental and drug-resistant HEY cell lines was
determined by DuoSet ELISA (A) and immunoblot (B) analyses as described in the Materials and Methods section. (C) Relative percentages
of enzastaurin-dependent decrease of phosphorylated GSK3β in the parental and chemoresistant HEY subclones.
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dephosphorylation of the MAP kinase ERK was also further decreased
by addition of pemetrexed after 48 hours of treatment (Figure 6).
Discussion
The biggest problem in the treatment of ovarian cancer is the fast-
emerging resistance against currently applied drugs (mainly platinum
and taxane derivates) observed in patients. In the recent past, great ef-
forts have been made to develop new molecular therapies to potentiate
the effectiveness of current cytostatic drugs and to overcome chemo-
therapy resistance. Many of these new drugs affect signaling pathways
that interfere with the induction of apoptosis and inhibition of prolif-
eration. PKC activity has been implicated in the regulation of tumor-
induced angiogenesis, tumor cell proliferation, and tumor invasiveness.
Enzastaurin, an ATP-competitive, selective inhibitor of PKCβ, was
shown to exhibit a direct effect on human tumor cells, inducing apop-
tosis in, and suppressing proliferation of, a wide array of cultured
human tumor cells. Enzastaurin treatment was reported to interfere
with signaling through the AKT pathway, suppressing phosphorylation
of GSK3β in various tumor cells, for example, human glioma cells [32]
and human xenograft tissues [23], suggesting that GSK3β phosphory-
lation may serve as a reliable pharmacodynamic marker of enzastaurin
activity. In our investigation, we could demonstrate a dose-dependent
inhibition of proliferation in the parental ovarian carcinoma cell line
HEY and in the subclones with resistance against cisplatin, etoposide,
docetaxel, paclitaxel, pemetrexed, and gemcitabine, respectively, after
Figure 4. Cotreatment of pemetrexed and enzastaurin exhibited synergistically antiproliferative effects on parental and chemoresistant
HEY cell lines. Investigation of single and concomitant stimulation with 5 μM enzastaurin and 50 nM pemetrexed for 72 hours was done
by MTS assay as described in the Materials and Methods section.
Figure 3. Effects of enzastaurin on AKT and theMAP kinase ERK1/2. (A) Parental HEY cells were treatedwith 10 μMenzastaurin for indicated
times, and both phosphorylated and total amount of protein expression were determined by immunoblot experiments with the appropriate
antibodies. Expression analysis of β-actin served as loading control. (B) Histograms show densitometrical analyses of the phosphorylated
and total amount of the protein expression of AKT and the MAP kinase ERK1/2 normalized to the protein expression of β-actin.
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enzastaurin treatment. As also described in other studies, the IC50 values
varied greatly [32,33]. The strongest sensitivity is displayed by the
cisplatin-resistant cell line, which responded even more clearly to enzas-
taurin than the parental HEYs. This is interesting because platinum
resistance in ovarian carcinoma is correlated with bad prognosis and
seemed to be partially overcome by enzastaurin stimulation in vitro.
In contrast, 16 μM enzastaurin was needed to inhibit 50% of prolifer-
ation in the docetaxel-resistant cells. Little is known about cross resis-
tances with enzastaurin; Lee et al. [33] described enzastaurin-dependent
induction of apoptosis in gastric cancer cell lines and additive or syner-
gistic effects after combined treatment with either cisplatin or paclitaxel.
To evaluate the different responses to enzastaurin treatment in the
parental and cytostatic-resistant cell lines, the known targets of enzas-
taurin PKCβII and GSK3β were investigated. Similar to a previous
work [34], the amount of both activated and total PKCβII protein
did not correlate with chemosensitivity to enzastaurin, neither in un-
treated (Figure W1) nor in enzastaurin-treated cells (data not shown).
In line with previous observations, we also detected dephosphorylation
of GSK3β already after 30 minutes of enzastaurin treatment in the
parental and the chemoresistant cell lines (Figure 2). Furthermore,
we could demonstrate that dephosphorylation and thus activation of
GSK3β correlates with the enzastaurin-induced proliferation inhibi-
tion: Themost enzastaurin-sensitive cisplatin-resistant subclone showed
the strongest GSK3β dephosphorylation, whereas the more resistant
docetaxel-resistant cell line displayed less dephosphorylation of GSK3β.
Enzastaurin-caused dephosphorylation of GSK3β was mostly linked
to the PI3K/AKT pathway. Down-regulation of AKT and GSK3β
was apparent at the same treatment periods [23,34]. In our study, ex-
pression of phosphorylated AKT also showed a distinct decrease with
enzastaurin but only after 48 hours of stimulation. Rizvi et al. [25],
who made the same observation, explained that the loss of inactive
GSK3β at an earlier time point may have been due to PKC inhibition
alone. Graff et al. [23] also described a delay of dephosphorylation of
AKT relative to enzastaurin-caused inhibition of GSK3β phosphoryla-
tion, but in contrast to our results, they showed a dephosphorylation of
AKTalready after 4 hours. Another indicator of the different regulation
in our ovarian cancer cell line is the persisting dephosphorylation of
GSK3β after 48 hours of enzastaurin treatment compared with un-
treated cells. In xenograft tissue samples, a time-dependent suppression
of phosphorylated GSK3β up to 8 hours was described, which returned
to pretreatment levels after 12 hours of dosing [23]. Our ovarian cancer
cell line showed the strongest dephosphorylation of GSK3β after
12 hours of enzastaurin exposition resembling the observation we in-
vestigated for enzastaurin-caused dephosphorylation of the MAP kinase
ERK1/2 (Figure 6). This is consistent with earlier studies that suggest
that activation of ERK1/2 can also phosphorylate GSK3β and promote
cell survival in addition to the PI3K/AKT pathway [35,36]. Previous
reports demonstrated that a PKC activator phorbol 12-myristate 13-
acetate increased prostaglandin E2 release resulting in activation of
PKCβ, ERKs, and p38 MAP kinase in murine macrophages [37].
Furthermore, Langford et al. [38] suggested a cross talk betweenGSK3β
and ERK1/2 that is possibly mediated by PKC in fibroblast growth
factor 2–stimulated human umbilical vein endothelial cells. Recently,
some studies have focused on how PKCβ collaborates with MAP kinase
signaling pathways to regulate cell survival and cell death [39,40]. Our
study demonstrated a distinct enzastaurin-dependent regulation of the
ERK1/2 pathway with a concordant phosphorylation pattern, as shown
for GSK3β. Consistent with these findings, Podar et al. [24] determined
that enzastaurin specifically inhibits 12-O-tetradecanoyl-phorbol-13-
acetate–triggered phosphorylation of signaling molecules downstream
of PKC, namely, GSK3β and ERK1/2. Concordant with our findings,
Guo et al. [41] revealed the important role of the PKCβ/ERK1/2 path-
way: Both the selective PKCβII inhibitor enzastaurin and PKCβII small
interfering RNA decreased the phosphorylation of ERK1/2 in metastatic
Figure 5. Effects of cotreatment of enzastaurin and pemetrexed on the proapoptotic proteins PARP, caspase 8, and caspase 9. (A) Parental
HEY cells were treated with both 10 μM enzastaurin and 10 μMenzastaurin plus 50 nM pemetrexed for the indicated times, and cleavage in
the proapoptotic active forms was determined by immunoblot experiments with the appropriate antibodies. Expression analysis of β-actin
served as loading control. (B) Histograms show densitometrical analyses of the full length and cleaved amount of PARP, caspase 8, and
caspase 9 normalized to the protein expression of β-actin.
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hepatocellular carcinoma cell lines. Our observation of the slight increase
of ERK1/2 phosphorylation after 24 hours of drug treatment may con-
tribute to growth proliferation being a sort of mechanism that cancer cells
use to escape drug-induced death.
Because enzastaurin only partially inhibited the proliferation of our
ovarian cancer cell lines at clinically achievable concentrations, cotreat-
ment with the multitargeted antifolate pemetrexed was supposed to
enhance enzastaurin-induced effects. Pemetrexed is well tolerated
and has been associated with a significant reduction of phosphorylated
AKTas well as a synergistic antiproliferative effect in combination treat-
ment with gemcitabine in human NSCLC cells [29]. Given in combi-
nation with cisplatin, pemetrexed has recently been approved for the
treatment of malignant pleural mesothelioma and as a second-line treat-
ment of NSCLC [42]. In our study, we could prove a synergistic pro-
liferation inhibition in the parental and all drug-resistant HEY cell lines
by concomitant treatment of enzastaurin and pemetrexed. Even the
docetaxel-resistant HEY cells, which displayed a partial enzastaurin as
well as pemetrexed resistance, were affected by this combination.
Apoptosis induction was investigated by PARP and caspase cleavage
analyses and confirmed a synergistic effect of cotreatment in the parental
HEY cell line. Partial PARP cleavage occurred after 48 hours of enzas-
taurin treatment. Combined treatment with pemetrexed resulted in
nearly completely cleaved PARP, demonstrating increased induction of
apoptosis. Investigation of the initiator caspases 8 and 9 also displayed
a slight cleavage into the proapoptotic active proteins by enzastaurin
exposition, which was additionally enforced by concomitant admin-
istration of pemetrexed. The apoptotic induction by enzastaurin was
mediated through the activation of caspase 9 in the parental ovarian
cancer cell line HEY, where an enzastaurin-resistant control cell line
showed no caspase 9 cleavage after enzastaurin treatment (Figure W2).
Cleavage of caspase 8 could be detected in both cell lines. This observa-
tion suggests that the mitochondrial apoptotic pathway is involved
in enzastaurin-induced ovarian cancer cell death. Similar results were
described by Rieger et al. [43] in glioma cell lines. They showed that
enzastaurin-induced apoptosis involved cleavage of both caspases
8 and 9, which was strongly suppressed by the common caspase inhibi-
tor zVAD-fmk but only slightly by the expression of a special caspase
8 inhibitor.
In 2005, Oberschmidt et al. [44] already described a synergistic anti-
tumor activity in thyroid cancer cell lines. In contrast, in the studies
of Hanauske et al. [45,46], enzastaurin gave no additional activity to
pemetrexed after long-term treatment. Morgillo et al. [47] compared
sequential with concomitant stimulation in a panel of NSCLC cells
and found that only a synergistic antiproliferative and proapoptotic
activity was obtained when pemetrexed was followed by treatment of
enzastaurin. In their study, the concomitant combination treatment
caused a decrease in IC50 values for the single treatment of enzastaurin
in the most enzastaurin-resistant NSCLC cell line Calu-3. We could
Figure 6. Effects of cotreatment of enzastaurin and pemetrexed on the proproliferative kinases GSK3β, AKT, and ERK1/2. (A) Parental
HEY cells were treated with both 10 μM enzastaurin and 10 μM enzastaurin plus 50 nM pemetrexed for indicated times. Phosphorylation
and total protein amount of GSK3β, AKT, and ERK1/2 were determined by immunoblot experiments with the appropriate antibodies.
Expression analysis of β-actin served as loading control. (B) Histograms show densitometrical analyses of the phosphorylated and total
amount of the protein expression of GSK3β, AKT, and the MAP kinase ERK1/2 normalized to the protein expression of β-actin.
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prove a similar effect for our docetaxel-resistant cell line. Interestingly,
the sequential combination treatment, which led to synergistic anti-
proliferative and proapoptotic activity in this study, also resulted in
enhanced dephosphorylation of ERK1/2 and AKT. Our observations
also showed synergistic antiproliferative and proapoptotic effects by
concordant treatment in the ovarian cancer cell line HEY, which are
associated with the enhanced inhibition of the proproliferative kinases
ERK1/2 and AKT. Moreover, the recently published investigation of
Tekle et al. [48] revealed strong synergistic effects by cotreatment of
enzastaurin and pemetrexed in simultaneous treatment as well as in
the sequential schedule in NSCLC cells. Similar to our results, a further
decrease of phosphorylation of AKT by simultaneous cotreatment
could be observed. Although the drug combination showed enhance-
ment of phosphorylated ERK1/2 in the investigation of Tekle et al. [48],
single treatment with enzastaurin displayed a strong decrease in the ac-
tivated MAP kinase, confirming our results.
Conclusions
In the present study, we showed that enzastaurin exhibited direct anti-
tumor activity, inducing tumor cell apoptosis and suppressing tumor
cell proliferation in the ovarian cancer cell line HEY and in the chemo-
resistant subclones, most prominent in the cisplatin-resistant HEYs. Be-
sides influencing its target GSK3β, enzastaurin interferes with signaling
mainly through the ERK1/2 pathway, a pathway frequently activated
in a variety of human cancers, and the AKT pathway. In addition, we
could demonstrate a synergistic antiproliferative and proapoptotic effect
by the combined treatment with enzastaurin and pemetrexed. This
combination treatment also causes inhibition of proliferation in partial
enzastaurin-resistant cells at achievable clinical concentrations with the
most promising effect in the docetaxel-resistant HEYs. Therefore, this
combination warrants clinical testing to overcome chemotherapy resis-
tance in ovarian cancer.
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Table W1. Determination of IC50 Values of Appropriate Cytostatic Drugs in the Parental and Chemoresistant HEY Cell Lines.
IC50 Cisplatin Etoposide Docetaxel Paclitaxel Pemetrexed Gemcitabine Enzastaurin
Parental HEYs 0.7 μg/ml 0.5 μg/ml 1.4 ng/ml 3.4 ng/ml 0.06 μM 0.1 μM 8.6 μM
Cisplatin HEYs 7.5 μg/ml
Etoposide HEYs 78.8 μg/ml
Docetaxel HEYs 76.3 ng/ml
Paclitaxel HEYs 453.0 ng/ml
Pemetrexed HEYs 336.2 μM
Gemcitabine HEYs 19.8 μM
Enzastaurin HEYs 29.4 μM
The parental HEY cells and the cytostatic drug-resistant subclones were treated with rising concentrations of the subsequent drugs and the appropriate IC50 values were investigated byMTS assay from Promega.
Figure W1. Differences in PKCβII protein expression determined by immunoblot analysis of total cell protein extracts in untreated pa-
rental and drug-resistant HEYs. The expression level of phosphorylated PKCβII resembled the total amount of PKCβII. Analyses of β-actin
served as loading control. HEY indicates parental HEY cell line; Cis, cisplatin-resistant HEY cell line; Eto, etoposide-resistant HEY cell
line; Doce, docetaxel-resistant HEY cell line; Pacli, paclitaxel-resistant HEY cell line; Gem, gemcitabine-resistant HEY cell line; Pem,
pemetrexed-resistant HEY cell line; PKC, PKCβII peptide, positive control.
Figure W2. Enzastaurin-resistant cells were treated with both 10 μM enzastaurin and the combination of 10 μM enzastaurin and 50 nM
pemetrexed for 48 hours. Cleavage of caspases 8 and 9 was determined by immunoblot analyses.
